Results 251 to 260 of about 2,018,696 (384)
Interobserver and intraobserver agreement of ligamentous injuries on conventional MRI after simple elbow dislocation [PDF]
Marc Schnetzke +8 more
openalex +1 more source
Abstract Background Flexion tests are commonly used in equine locomotion examinations to identify underlying locomotor issues, yet their neuromuscular effects remain poorly understood. Response variability raises concerns about their clinical value in lameness assessments and pre‐purchase evaluations.
Marijke Jonkhart +4 more
wiley +1 more source
Lawnmower Poetry and the Poetry of Lawnmowers
Critical Quarterly, EarlyView.
Francesca Gardner
wiley +1 more source
HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia B
ABSTRACT Introduction Haemophilia B is an X‐linked recessive bleeding disorder caused by coagulation factor IX (FIX) deficiency. Treatment involves intravenous replacement of FIX. Recently, extended half‐life (EHL) FIX products have been introduced alongside standard half‐life (SHL) products to optimize therapy. Aim This study evaluated bleeding rates,
Jasmin Lonardi +11 more
wiley +1 more source
Smart Tennis Racquet With Tennis Elbow Injury Prevention
Malick Basha, G. Nallavan
openalex +2 more sources
Longitudinal assessment of the upper limb in adults with cerebral palsy
Developmental Medicine &Child Neurology, EarlyView.
Prue Morgan
wiley +1 more source
ABSTRACT Background In patients with unexplained bleeding and normal haemostatic parameters, heritable disorders of connective tissue (HDCT) may be an underlying cause due to vascular fragility, as observed in Ehlers–Danlos syndrome (EDS) or Marfan syndrome (MS). This study aims to investigate the molecular profile of patients with joint hypermobility (
Perla Bandini +11 more
wiley +1 more source
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang +3 more
wiley +1 more source

